Page last updated: 2024-12-08

yomogin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

yomogin: eudesmane sesquiterpene from Artemisia princeps; inhibits inducible nitric oxide synthase production in macrophages; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
ArtemisiagenusA plant genus of the family ASTERACEAE with strong-smelling foliage. It is a source of SANTONIN and other cytotoxic TERPENES.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID174865
CHEMBL ID4547184
MeSH IDM0301191

Synonyms (9)

Synonym
yomogin
(3ar,8as,9ar)-5,8a-dimethyl-3-methylidene-3a,4,9,9a-tetrahydrobenzo[f][1]benzofuran-2,6-dione
naphtho(2,3-b)furan-2,6(3h,4h)-dione, 3a,8a,9,9a-tetrahydro-5,8a-dimethyl-3-methylene-, (3ar-(3aalpha,8abeta,9aalpha))-
2-naphthaleneacetic acid, 1,2beta,3,4,4a,7-hexahydro-3alpha-hydroxy-4aalpha,8-dimethyl-alpha-methylene-7-oxo-, gamma-lactone
10067-18-2
1,2beta,3,4,4a,7-hexahydro-3alpha-hydroxy-4aalpha,8-dimethyl-alpha-methylene-7-oxo-2-naphthaleneacetic acid gamma-lactone
DTXSID50143436
CHEMBL4547184
AKOS040754536

Research Excerpts

Overview

Yomogin is an active compound isolated from Artemisia princep, a traditional Oriental medicinal herb. It has been shown to inhibit tumor cell proliferation.

ExcerptReferenceRelevance
"Yomogin is an active compound isolated from Artemisia princep, a traditional Oriental medicinal herb, which has been shown to inhibit tumor cell proliferation. "( Induction of apoptosis by yomogin in human promyelocytic leukemic HL-60 cells.
Ha, JH; Jeong, SH; Koo, SJ; Lee, KT; Park, HJ; Ryu, SY, 2004
)
2.07

Treatment

ExcerptReferenceRelevance
"Yomogin-treated HL-60 cells displayed several features of apoptosis, including DNA fragmentation, formation of DNA ladders in agarose gel electrophoresis, and externalization of annexin-V targeted phosphatidylserine residues."( Induction of apoptosis by yomogin in human promyelocytic leukemic HL-60 cells.
Ha, JH; Jeong, SH; Koo, SJ; Lee, KT; Park, HJ; Ryu, SY, 2004
)
1.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1546530Cytotoxicity against human XF498 cells by SRB assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1675634Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID1546527Cytotoxicity against human A549 cells by SRB assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1546529Cytotoxicity against human SKOV3 cells by SRB assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1675636Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID1546531Cytotoxicity against human HCT15 cells by SRB assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1546528Cytotoxicity against human SK-MEL-2 cells by SRB assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Artemisia: a promising plant for the treatment of cancer.
AID1675635Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's5 (55.56)29.6817
2010's1 (11.11)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.70 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]